BerGenBio: Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. Stage 2 of Ph 2 combination trial with bemcentinib/KEYTRUDA in NSCLC expected in 1H19. Bemcentinib/TARCEVA Ph 2 combination trial in first line EGFRm patients reported that median PFS surpassed TARCEVA monotherapy.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Listing
Europe, Public
Market Cap
<100MM
Website:
Address:
Jonas Lies vei 91
Bergen, 5009
Norway

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.